MedTrace Logo

Repolarization and Activation Mapping in Ventricular Tachycardia Ablation: the REDEMPTION Study

NCT06765746 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-01-09

No results posted yet for this study

Summary

The aim of this study is to prospectively evaluate a novel sinus rhythm mapping strategy for ventricular tachycardia (VT) ablation based on combined ventricular repolarization and activation (depolarization) mapping (REpolarization DEpolarization Mapping, REDEEM mapping). Furthermore, gathering clinical data on VT ablation with TactiFlex is also aimed.

Conditions

  • Ventricular Tachycardia Ablation

Interventions

PROCEDURE

Ventricular tachycardia ablation

All ventricular tachycardia (VT) ablation procedures will be performed under general anesthesia. An epicardial approach will be performed, if clinically needed, when a detailed endocardial mapping during VT fails to reveal the complete VT critical isthmus. In case of epicardial mapping, the pericardium will be accessed percutaneously using the method described by Sosa et al. VT activation mapping will be performed and the critical isthmus will be defined as the diastolic pathway. Ablation will be performed at 50 W (temperature limit of 43 °C) using an irrigated ablation catheter (TactiFlex, Abbott, MN). Ablation will be aimed at VT isthmus transection. Substrate modification will be added if the patient is still inducible or in the absence of any inducible/tolerated VT. Substrate ablation will be performed based on sinus rhythm mapping, aiming at non-inducibility of any VT. At the end of procedure, programmed ventricular stimulation will be repeated.

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-06-01
Completion
2027-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765746 on ClinicalTrials.gov